[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0716762A2 - melhorias da cultura celular - Google Patents

melhorias da cultura celular

Info

Publication number
BRPI0716762A2
BRPI0716762A2 BRPI0716762-8A2A BRPI0716762A BRPI0716762A2 BR PI0716762 A2 BRPI0716762 A2 BR PI0716762A2 BR PI0716762 A BRPI0716762 A BR PI0716762A BR PI0716762 A2 BRPI0716762 A2 BR PI0716762A2
Authority
BR
Brazil
Prior art keywords
cell culture
culture improvements
cell
culture
Prior art date
Application number
BRPI0716762-8A2A
Other languages
English (en)
Inventor
Itzcoatl A Pla
Joseph C Matuck
John C Fann
Christof Schulz
Nicole A Roy
David F Bruton
James Mcintire
Yu-Hsiang David Chang
Thomas Seewoester
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39184386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0716762(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0716762A2 publication Critical patent/BRPI0716762A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0716762-8A2A 2006-09-13 2007-09-13 melhorias da cultura celular BRPI0716762A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84515806P 2006-09-13 2006-09-13
US87637406P 2006-12-21 2006-12-21
PCT/US2007/020027 WO2008033517A2 (en) 2006-09-13 2007-09-13 Cell culture improvements

Publications (1)

Publication Number Publication Date
BRPI0716762A2 true BRPI0716762A2 (pt) 2013-09-24

Family

ID=39184386

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716762-8A2A BRPI0716762A2 (pt) 2006-09-13 2007-09-13 melhorias da cultura celular

Country Status (17)

Country Link
US (11) US8093045B2 (pt)
EP (4) EP2500413A1 (pt)
JP (3) JP5878682B2 (pt)
KR (2) KR20140132017A (pt)
CN (6) CN103397065A (pt)
AU (1) AU2007294731B2 (pt)
BR (1) BRPI0716762A2 (pt)
CA (5) CA2842966A1 (pt)
IL (1) IL197444A0 (pt)
MX (4) MX346523B (pt)
MY (4) MY185872A (pt)
NO (1) NO20091439L (pt)
NZ (2) NZ575328A (pt)
RU (2) RU2518289C2 (pt)
SG (3) SG10201510384UA (pt)
TW (4) TW201708537A (pt)
WO (1) WO2008033517A2 (pt)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040136991A1 (en) * 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of anemia using TNFalpha inhibitors
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
WO2007089303A2 (en) * 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
EP2004689A4 (en) 2006-04-05 2010-06-02 Abbott Biotech Ltd PURIFICATION OF ANTIBODIES
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
TWI542374B (zh) 2006-06-30 2016-07-21 艾伯維生物技術有限責任公司 自動注射裝置
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
JP2010507670A (ja) 2006-10-27 2010-03-11 アボツト・バイオテクノロジー・リミテツド 結晶性抗ｈＴＮＦα抗体
EP2528002B1 (en) * 2007-04-16 2015-11-04 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
JP5576115B2 (ja) * 2007-04-26 2014-08-20 中外製薬株式会社 高濃度アミノ酸含有培地を用いた細胞の培養方法
EP2679996A1 (en) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
PL2586788T3 (pl) 2007-07-09 2018-05-30 Genentech, Inc. Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
CA2693771A1 (en) * 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
RU2010107994A (ru) 2007-08-08 2011-09-20 Эбботт Лэборетриз (Us) Композиции и способы кристаллизации антител
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8415094B2 (en) * 2007-12-21 2013-04-09 Jaffar Ali bin M. Abdullah Protein-free gamete and embryo handling and culture media products
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
JP2011510267A (ja) * 2008-01-03 2011-03-31 アボツト・バイオテクノロジー・リミテツド 乾癬の治療における化合物の長期的効力の予測
JP5431361B2 (ja) 2008-01-09 2014-03-05 セルカ ゲーエムベーハー 改善された培養培地添加物及びそれを用いる方法
RU2537139C2 (ru) 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
WO2010016943A2 (en) 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
JP4883067B2 (ja) 2008-09-29 2012-02-22 株式会社日立プラントテクノロジー 培養装置及び培養方法
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
CA2751021A1 (en) 2008-12-30 2010-07-08 Baxter International Inc. Method of enhancing cell growth using alkyl-amine-n-oxide (aanox)
JP5677411B2 (ja) 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
WO2010128159A1 (en) 2009-05-07 2010-11-11 Hemarina Novel heamoglobin and uses thereof
SG176217A1 (en) 2009-05-28 2011-12-29 Boehringer Ingelheim Int Method for a rational cell culturing process
KR20120031083A (ko) * 2009-07-24 2012-03-29 에프. 호프만-라 로슈 아게 교반기 시스템
SG10201901417UA (en) 2009-08-11 2019-03-28 Genentech Inc Production of proteins in glutamine-free cell culture media
TWI584838B (zh) 2009-12-15 2017-06-01 艾伯維生物技術有限責任公司 用於自動注射裝置之改良發射按鈕
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
RU2577972C2 (ru) * 2010-04-26 2016-03-20 Новартис Аг Способ получения рекомбинантного полипептида
JP5944382B2 (ja) 2010-06-03 2016-07-05 アッヴィ バイオテクノロジー リミテッド 汗腺膿瘍（ｈｓ）の治療のための使用および組成物
KR101894604B1 (ko) * 2010-07-08 2018-09-03 박스알타 인코퍼레이티드 세포 배양에서 재조합 고분자량 ｖＷＦ를 생산하는 방법
JP2013536683A (ja) * 2010-08-31 2013-09-26 フリエスランド ブランズ ビー．ブイ． 真核細胞のための培養培地
CA2815689C (en) 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
EP2667918B1 (en) 2011-01-24 2017-03-01 AbbVie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
WO2012110435A1 (en) * 2011-02-14 2012-08-23 Basf Se Bio process additives
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2784146T5 (es) * 2011-10-21 2024-06-04 Pfizer Adición de hierro para mejorar el cultivo celular
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
EP4148122A1 (en) 2012-05-02 2023-03-15 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AR093460A1 (es) * 2012-11-14 2015-06-10 Merck Patent Ges Mit Beschränkter Haftung Medios de cultivo celular
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9611455B2 (en) 2013-03-13 2017-04-04 Merck Sharp & Dohme Corp. Adapted lepidopteran insect cells for the production of recombinant proteins
WO2014151878A2 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
CA2926301A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151901A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Improvement of mammalian cell culture performance through surfactant supplementation of feed media
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201507365VA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US10138467B2 (en) * 2013-10-14 2018-11-27 Ares Trading S.A. Medium for high performance mammalian fed-batch cultures
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3083933A1 (en) * 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP2923707A1 (en) 2014-03-28 2015-09-30 Hemarina Blood substitute with respiratory pigment
PE20161326A1 (es) 2014-04-10 2016-12-11 Bayer Healthcare Llc Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular
KR101699761B1 (ko) * 2014-05-23 2017-01-25 주식회사 비비에이치씨 플로로탄닌 분획물을 이용한 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하는 방법
JP6695814B2 (ja) 2014-06-04 2020-05-20 アムジエン・インコーポレーテツド 哺乳類細胞培養物を回収するための方法
WO2015195758A1 (en) * 2014-06-18 2015-12-23 Medimmune, Llc Cell culture methods and media comprising n-acetylcysteine
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
US10435464B1 (en) 2014-09-05 2019-10-08 Coherus Biosciences, Inc. Methods for making recombinant proteins
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105820246A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
SG11201707857VA (en) * 2015-03-30 2017-10-30 Ajinomoto Kk Chelated iron-containing culture medium for neural stem cells
CN106190948B (zh) * 2015-05-07 2020-09-25 上海津曼特生物科技有限公司 一种cho-s细胞半固体培养基及其配制方法与应用
CN105018425B (zh) * 2015-07-09 2018-09-28 广州白云山拜迪生物医药有限公司 一种无动物来源成分的外周血淋巴细胞培养基
CA2992096A1 (en) * 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
CN105441378A (zh) * 2015-12-22 2016-03-30 肇庆大华农生物药品有限公司 一种培养Vero细胞用的无血清培养基及其制备方法
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2017146646A1 (en) * 2016-02-22 2017-08-31 Agency For Science, Technology And Research Cell culture medium
JP6997079B2 (ja) * 2016-05-10 2022-01-17 三菱商事ライフサイエンス株式会社 培地用組成物
CN105794772A (zh) * 2016-05-16 2016-07-27 天津市中奥天元科技发展有限公司 一种无血清细胞冻存液
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106635974B (zh) * 2016-10-19 2020-10-27 浙江译美生物科技有限公司 一种人脐带间充质干细胞的分离和培养方法
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
ES2926028T3 (es) 2016-12-23 2022-10-21 Serum Institute Of India Pvt Ltd Métodos para potenciar la productividad de anticuerpos en cultivos de células de mamíferos y minimizar la agregación durante los procesos de formulación corriente abajo y las formulaciones de anticuerpos estables obtenidas de los mismos
CN110520538B (zh) * 2017-03-31 2024-02-20 勃林格殷格翰国际公司 灌注培养基
US10280217B2 (en) 2017-09-19 2019-05-07 American Air Liquide, Inc. Cell culture additives and their use for increased bioprotein production from cells
CN107904200B (zh) * 2017-10-20 2018-10-16 通化东宝生物科技有限公司 一种表达阿达木单抗的联合培养基及其应用
JPWO2019088143A1 (ja) * 2017-11-01 2020-11-12 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
US20210171901A1 (en) * 2017-11-16 2021-06-10 Life Technologies Corporation Streamlined methods for making liquid media
US20200385673A1 (en) * 2017-11-30 2020-12-10 Hoffmann-La Roche Inc. Process for culturing mammalian cells
EP3492582A1 (en) * 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods
HUE069711T2 (hu) * 2018-03-16 2025-04-28 Genzyme Corp Eljárások sejt életképességének javítására termelõ bioreaktorban
EP3775251A1 (en) 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CA3099917A1 (en) * 2018-05-24 2019-11-28 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
RS65472B1 (sr) * 2018-07-03 2024-05-31 Bristol Myers Squibb Co Postupak proizvodnje rekombinantnih proteina
KR20210041003A (ko) * 2018-07-27 2021-04-14 아지노모토 가부시키가이샤 동물 세포의 부유 배양용 첨가물, 부유 배양용 배지 및 부유 배양 방법
CN109337861B (zh) * 2018-11-12 2021-06-25 友康恒业生物科技（北京）有限公司 一种支持产物高表达的cho细胞无血清培养基
WO2020132583A1 (en) * 2018-12-21 2020-06-25 Gloriana Therapeutics Sarl Mammalian cell culture-produced neublastin antibodies
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
KR20220097421A (ko) * 2019-11-05 2022-07-07 아지노모토 가부시키가이샤 단백질의 제조 방법
CN114206907A (zh) 2019-12-06 2022-03-18 瑞泽恩制药公司 抗vegf蛋白组合物及其制备方法
CN111233996A (zh) * 2020-01-20 2020-06-05 北京交通大学 一种将丁酸钠用于促进工程细胞株分泌表达rhIL-24的方法
CA3177567A1 (en) * 2020-03-31 2021-10-07 Cell Exosome Therapeutics Inc. Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
JP7521738B2 (ja) * 2020-05-18 2024-07-24 キヤノン株式会社 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地
CN112592948B (zh) * 2020-12-16 2023-05-09 广州汉腾生物科技有限公司 动物细胞的灌流培养方法
WO2022154762A1 (en) * 2021-01-18 2022-07-21 Turgut İlaçlari A.Ş. Method of producing adalimumab
WO2022221511A1 (en) * 2021-04-14 2022-10-20 Genzyme Corporation Methods of perfusion culturing a mammalian cell
KR102817880B1 (ko) * 2021-11-17 2025-06-10 주식회사 웰진 무혈청 세포 배양 배지 조성물 및 이의 용도
KR102817881B1 (ko) * 2021-11-17 2025-06-10 주식회사 웰진 저혈청 배지 첨가제 및 이의 용도
CN114230669B (zh) * 2021-12-24 2024-01-30 天士力生物医药股份有限公司 一种双特异性抗体的生产方法
EP4484567A1 (en) * 2022-02-21 2025-01-01 Chugai Seiyaku Kabushiki Kaisha Perfusion culture method
AU2023374004A1 (en) * 2022-10-31 2025-05-01 Samsung Bioepis Co., Ltd. Method for preparing high-concentration liquid medium
CN116064374A (zh) * 2023-02-27 2023-05-05 内蒙古奥普赛生物科技有限公司 一种即用型无菌mem液体培养基的制备方法及其产品
KR20240177497A (ko) * 2023-06-20 2024-12-27 (주)엑셀세라퓨틱스 세포 특성 맞춤형 배지 조성 설계 플랫폼
WO2025128947A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Combinations of polysaccharides and polyether surfactants
WO2025128955A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Effects of differing viscosity-grade cellulose derivatives on cellular growth
WO2025128951A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Cell culture media containing cellulose derivatives and associated method
WO2025128949A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Protective effect of polysaccharides on cell cultures containing anti-foam agents

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2289997T3 (es) 1991-03-18 2008-02-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
KR100255717B1 (ko) 1991-07-15 2000-05-01 그레이엄 브레레톤 항체의 생산방법
ATE274055T1 (de) 1991-10-25 2004-09-15 Immunex Corp Neue cytokine
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5741705A (en) 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
EP0832229B1 (en) 1995-06-07 2004-01-14 Immunex Corporation Cd40l mutein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
DK0873405T3 (da) 1996-01-11 2005-01-17 Immunex Corp Ekspressionsforøgende sekvenselementer (EASE) til eukaryote ekspressionssystemer
BRPI9707379B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
ES2180689T3 (es) 1996-04-19 2003-02-16 Nestle Sa Linea inmortalizada de celulas epiteliales del colon humano.
US20040171152A1 (en) 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
AU4751697A (en) 1996-10-10 1998-05-05 Douglas Danner Animal cell culture media comprising plant-derived nutrients
SI1900751T1 (sl) 1996-11-27 2010-03-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
AU1663599A (en) 1997-12-19 1999-07-12 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
JP4469933B2 (ja) 1998-05-06 2010-06-02 ジェネンテック， インコーポレイテッド イオン交換クロマトグラフィによるタンパク質精製
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
ATE414780T1 (de) 1998-07-01 2008-12-15 Takara Bio Inc Methoden für gentransfer mit retroviren
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US6190523B1 (en) 1999-07-20 2001-02-20 Basf Corporation Electrocoat coating composition and process for electrocoating a substrate
PT1650307E (pt) 1999-09-27 2010-10-21 Genentech Inc Métodos para preparação de proteínas recombinantes utilizando inibidores de apoptose
DE60024659T2 (de) 1999-10-13 2006-08-17 Immunex Corp., Thousand Oaks Vektoren und verfahren für rekombinante proteinexpression
AR026743A1 (es) 1999-12-09 2003-02-26 Pharmacia Ab Produccion de peptidos
JP2003521942A (ja) 2000-02-08 2003-07-22 ジェネンテック・インコーポレーテッド 組換え糖タンパク質の改善されたガラクトシル化
WO2001058956A2 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
AU2001246846A1 (en) * 2000-04-06 2001-10-23 Chugai Seiyaku Kabushiki Kaisha Immunoassay of anti-hm1.24 antibody
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP1175931A1 (en) 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
WO2002016590A2 (en) 2000-08-21 2002-02-28 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US7189820B2 (en) * 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
DE60213248T2 (de) 2001-06-05 2006-11-30 Genetics Institute, LLC, Cambridge Verfahren zur reinigung hochanionischer proteine
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
IL160170A0 (en) 2001-08-03 2004-07-25 Glycart Biotechnology Ag A host cell engineered to produce a polypeptide having increased cytotoxicity
JP4351049B2 (ja) 2001-10-02 2009-10-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核細胞中で組換えタンパク質を生産する方法
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
WO2003046162A2 (en) 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
HRP20040475A2 (en) 2001-11-28 2005-06-30 Sandoz Gmbh Cell culture process
DE60231651D1 (de) 2001-12-21 2009-04-30 Immunex Corp Proteinreinigungsverfahren
US20030201229A1 (en) 2002-02-04 2003-10-30 Martin Siwak Process for prefiltration of a protein solution
DK1472275T3 (da) 2002-02-05 2009-04-14 Genentech Inc Proteinoprensning
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
US20030190710A1 (en) 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040029229A1 (en) 2002-05-20 2004-02-12 Reeves Philip J. High level protein expression system
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US7208585B2 (en) 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
US6890736B1 (en) * 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
CA2508925C (en) * 2002-12-23 2012-08-28 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2004058800A2 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
PT1601697E (pt) 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK1623019T4 (en) 2003-05-15 2017-03-27 Wyeth Llc LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE
HUE050171T2 (hu) 2003-07-28 2020-11-30 Genentech Inc Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
JP4619362B2 (ja) * 2003-08-08 2011-01-26 メディミューン リミテッド トランスフェリン不含・低鉄培地中での骨髄腫細胞培養
ES2565077T3 (es) 2003-10-10 2016-03-31 Novo Nordisk Health Care Ag Método para producción en gran escala de un polipéptido en células eucariotas
EP1678208B1 (en) 2003-10-27 2013-05-15 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20070099266A1 (en) 2003-12-23 2007-05-03 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
CN1238498C (zh) * 2004-02-12 2006-01-25 陈志南 动物细胞无血清悬浮培养工艺过程控制参数的方法
WO2005087915A2 (en) 2004-03-08 2005-09-22 Biovest International, Inc. Use of ethanolamine for enhancing cell growth in membrane systems
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US20060018902A1 (en) 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
MXPA06012676A (es) 2004-05-04 2007-04-02 Novo Nordisk Healthcare Ag Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos.
US20060001890A1 (en) * 2004-07-02 2006-01-05 Asml Holding N.V. Spatial light modulator as source module for DUV wavefront sensor
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
SI2550971T1 (sl) 2004-09-30 2017-08-31 Bayer Healthcare Llc Naprave in postopki za integrirano kontinuirano izdelavo bioloških molekul
JP2008518597A (ja) 2004-10-29 2008-06-05 セントカー・インコーポレーテツド 化学的規定培地組成物
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP2006143601A (ja) 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
US8530192B2 (en) 2005-02-11 2013-09-10 Novo Nordisk Healthcare Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
MX2007011129A (es) 2005-03-11 2007-11-06 Wyeth Corp Un metodo de cromatografia de particion debil.
WO2006113743A2 (en) 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
US7247457B2 (en) 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
WO2006128764A2 (en) 2005-06-03 2006-12-07 Biovitrum Ab (Publ) Process for cultivating animal cells comprising the feeding of plant-derived peptones
EP1888638A2 (en) 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
CN101217979A (zh) 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
PE20070796A1 (es) 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
ES2564790T5 (es) 2005-12-08 2023-08-25 Amgen Inc Producción mejorada de glicoproteínas usando manganeso
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
JP5406710B2 (ja) 2006-05-19 2014-02-05 グライコフィ， インコーポレイテッド エリスロポエチン組成物
EP2069387A4 (en) 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
TR201807021T4 (tr) 2006-07-13 2018-06-21 Wyeth Llc Geliştirilmiş glikosilasyon şablonuna sahip pıhtılaşma faktörü ıx?un üretilmesi.
TW200821026A (en) 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
US10982250B2 (en) 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
EP2089424B1 (en) 2006-12-06 2015-07-01 JCR PHARMACEUTICALS Co., LTD. Method for production of human erythropoietin
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
MX2009010389A (es) 2007-03-30 2010-01-20 Medimmune Llc Formulacion de anticuerpos.
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
EP2528002B1 (en) 2007-04-16 2015-11-04 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
WO2008141207A1 (en) 2007-05-11 2008-11-20 Amgen Inc. Improved feed media
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
PL2586788T3 (pl) 2007-07-09 2018-05-30 Genentech, Inc. Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
ES2657055T3 (es) 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
DK2574676T3 (en) 2007-12-27 2017-10-09 Baxalta GmbH Methods of cell culture
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
JP2011512875A (ja) 2008-03-11 2011-04-28 ジェネンテック， インコーポレイテッド 増強されたａｄｃｃ機能を有する抗体
EP2271382B1 (en) 2008-04-15 2013-03-13 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010016943A2 (en) 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
CA2731943C (en) 2008-08-14 2016-11-29 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2340305A1 (en) 2008-09-26 2011-07-06 Eureka Therapeutics, Inc. Cell lines and proteins with variant glycosylation pattern
WO2010051360A1 (en) 2008-10-31 2010-05-06 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
CA2744510A1 (en) 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
ES2488542T3 (es) 2008-12-22 2014-08-27 F. Hoffmann-La Roche Ag Purificación de inmunoglobulinas
CN102272144B (zh) 2009-01-08 2014-09-17 通用电气健康护理生物科学股份公司 采用单一聚合物相系统的分离方法
EP2403866B1 (en) 2009-03-05 2018-05-02 Biogen MA Inc. Purification of immunoglobulins
JP5755136B2 (ja) 2009-03-27 2015-07-29 旭化成メディカル株式会社 高濃度モノクローナル抗体溶液中のウイルス除去方法
EP2419436A1 (en) 2009-04-13 2012-02-22 Bristol-Myers Squibb Company Protein purification by citrate precipitation
MX2011010989A (es) 2009-04-20 2012-02-28 Pfizer Control de glicosilacion de proteina y composiciones y metodos que se refieren a la misma.
SG176217A1 (en) 2009-05-28 2011-12-29 Boehringer Ingelheim Int Method for a rational cell culturing process
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
MX2012000354A (es) 2009-07-06 2012-02-01 Genentech Inc Metodo para cultivar celulas eucarionticas.
EP3404044A1 (en) 2009-07-24 2018-11-21 F. Hoffmann-La Roche AG Optimizing the production of antibodies
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
ES2662529T3 (es) 2009-08-06 2018-04-06 F. Hoffmann-La Roche Ag Procedimiento para mejorar la eliminación de virus en la purificación de proteínas
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011024025A1 (en) 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
CN108409829A (zh) 2009-09-01 2018-08-17 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
US20120232395A1 (en) 2009-11-10 2012-09-13 Hitachi Medical Corporation Ultrasonic diagnostic apparatus
WO2011065940A1 (en) 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
EP2507627A2 (en) 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
SG10201408384PA (en) 2009-12-18 2015-01-29 Novartis Ag Wash solution and method for affinity chromatography
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
WO2011134920A1 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell culture medium
RU2577972C2 (ru) 2010-04-26 2016-03-20 Новартис Аг Способ получения рекомбинантного полипептида
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
CN103080300B (zh) 2010-08-05 2015-11-25 安姆根有限公司 增加细胞培养物的产率和活力的二肽
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
EP2649087A1 (en) 2010-12-08 2013-10-16 Amgen Inc. Ion exchange chromatography in the presence of an amino acid
MX357821B (es) 2010-12-21 2018-07-25 Hoffmann La Roche Preparación de anticuerpo enriquecida con isoforma y método para obtenerla.
CA2821926A1 (en) 2011-01-07 2012-07-12 Abbvie Inc. Anti-il-12/il-23 antibodies and uses thereof
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
CN103582700B (zh) 2011-03-25 2016-08-17 弗·哈夫曼一拉罗切有限公司 新的蛋白质纯化方法
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
WO2012147048A2 (en) 2011-04-29 2012-11-01 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
US20120283419A1 (en) 2011-05-03 2012-11-08 Avantor Performance Materials, Inc. Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
DK2707383T3 (en) 2011-05-13 2018-07-23 Biogen Ma Inc PROCEDURES FOR PREVENTION AND REMOVAL OF TRISULPHIDE BINDINGS
ES2625045T3 (es) 2011-07-01 2017-07-18 Amgen Inc. Cultivo de células de mamífero
WO2013006461A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
KR20140077178A (ko) 2011-10-19 2014-06-23 로슈 글리카트 아게 푸코실화 항체의 분리 방법
US20140288278A1 (en) 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates

Also Published As

Publication number Publication date
AU2007294731A1 (en) 2008-03-20
EP2527425A1 (en) 2012-11-28
CN103276033A (zh) 2013-09-04
CN103397065A (zh) 2013-11-20
CN103555652A (zh) 2014-02-05
US8906646B2 (en) 2014-12-09
US9073988B2 (en) 2015-07-07
WO2008033517A2 (en) 2008-03-20
MX346523B (es) 2017-03-23
TWI548747B (zh) 2016-09-11
US20160186130A1 (en) 2016-06-30
JP2013230151A (ja) 2013-11-14
MY185040A (en) 2021-04-30
US20120077213A1 (en) 2012-03-29
US20140134675A1 (en) 2014-05-15
TWI456062B (zh) 2014-10-11
RU2014110141A (ru) 2015-09-27
US8093045B2 (en) 2012-01-10
US8663945B2 (en) 2014-03-04
US20140206038A1 (en) 2014-07-24
US20150125905A1 (en) 2015-05-07
EP2532737A3 (en) 2013-03-27
SG192441A1 (pt) 2013-08-30
NZ597334A (en) 2014-02-28
US20160039927A1 (en) 2016-02-11
RU2518289C2 (ru) 2014-06-10
CN101663390B (zh) 2013-10-23
SG10201510384UA (en) 2016-01-28
NO20091439L (no) 2009-05-28
US20190225934A1 (en) 2019-07-25
EP2532737A2 (en) 2012-12-12
JP2010503397A (ja) 2010-02-04
US20170130191A1 (en) 2017-05-11
US20150087024A1 (en) 2015-03-26
AU2007294731B2 (en) 2014-04-17
SG174804A1 (pt) 2011-10-28
CN103555651A (zh) 2014-02-05
TW200831669A (en) 2008-08-01
CN102337243A (zh) 2012-02-01
MX345141B (es) 2017-01-18
WO2008033517A9 (en) 2009-02-26
EP2500413A1 (en) 2012-09-19
CA2910619A1 (en) 2008-03-20
KR20090074040A (ko) 2009-07-03
CA2842964A1 (en) 2008-03-20
JP5878682B2 (ja) 2016-03-08
MY185887A (en) 2021-06-14
CN101663390A (zh) 2010-03-03
TW201516149A (zh) 2015-05-01
MX2009002748A (es) 2009-03-26
US20080227136A1 (en) 2008-09-18
EP2064314A2 (en) 2009-06-03
RU2009113613A (ru) 2010-10-20
CA2842959A1 (en) 2008-03-20
US20140134674A1 (en) 2014-05-15
KR20140132017A (ko) 2014-11-14
MX353340B (es) 2018-01-09
US9234032B2 (en) 2016-01-12
US10119118B2 (en) 2018-11-06
TW201708537A (zh) 2017-03-01
NZ575328A (en) 2012-06-29
WO2008033517A3 (en) 2008-11-27
EP2064314A4 (en) 2009-12-30
MY161866A (en) 2017-05-15
JP2016000030A (ja) 2016-01-07
CA2663442A1 (en) 2008-03-20
MY185872A (en) 2021-06-14
US9284371B2 (en) 2016-03-15
IL197444A0 (en) 2011-08-01
TW201346032A (zh) 2013-11-16
CA2842966A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
BRPI0716762A2 (pt) melhorias da cultura celular
PL2634242T3 (pl) Ulepszony sposób hodowli komórek
DK2522717T3 (da) Oligopeptid-frie cellekulturmedier
DE602007004421D1 (de) Zellkulturvorrichtung
BRPI0818536A2 (pt) Linhagem celular cho-k1
EP2005504A4 (en) ELECTROLYTE
BRPI0919919A2 (pt) transplante celular
CL2007002310S1 (es) Telefono celular.
EP2002009A4 (en) ANAEROBIC FERMENTATION OF GLYCEROL
EP2095430A4 (en) SOLAR CELL
BRPI0816956A2 (pt) Célula de combustível
EP2128242A4 (en) CELL CULTURE MODULE
DE112006000958B8 (de) Brennstoffzelle
EP2028264A4 (en) CELL INCUBATOR
DE112007002407B8 (de) Brennstoffzelle
DE112007001371B8 (de) Brennstoffzelle
DE602006012891D1 (de) Brennstoffzellenseparator
BRPI0714209A2 (pt) Induzidor de morte celular
DK2027150T3 (da) Allo-begrænsede peptid-specifikke t-celler
DE602007008627D1 (de) Zellkulturmedium
BRPI0814572A2 (pt) Célula de lítio
DE602006001060D1 (de) Brennstoffzelle
DE112007003333A5 (de) Fermenter
BRPI0813726A2 (pt) Célula de lítio
DE602007007302D1 (de) Brennstoffzelle

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15W Others matters related to applications: legal action concerning application
B15N Others concerning applications: notification of judicial decision
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time